N1-(2-(吡咯烷-1-基)乙基)苯-1,4-二胺 | 863453-84-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N1-(2-(吡咯烷-1-基)乙基)苯-1,4-二胺
• 英文名称: N-(2-pyrrolidin-1-ylethyl)benzene-1,4-diamine
• 英文别名: (4-aminophenyl)[2-(1-pyrrolidinyl)ethyl]amine；N~1~-[2-(Pyrrolidin-1-yl)ethyl]benzene-1,4-diamine；4-N-(2-pyrrolidin-1-ylethyl)benzene-1,4-diamine
• CAS: 863453-84-3
• 化学式: C₁₂H₁₉N₃
• 分子量: 205.303
• InChiKey: HDWIOQFBQKXYBZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  41.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N1-(2-(吡咯烷-1-基)乙基)苯-1,4-二胺 、 4-氯-2,3-二甲基喹啉 在 盐酸 作用下， 以 甲醇 为溶剂， 反应 0.25h， 以96%的产率得到4-N-(2,3-dimethylquinolin-4-yl)-1-N-(2-pyrrolidin-1-ylethyl)benzene-1,4-diamine
  参考文献：
  名称：

  Structure−Activity Relationship of Quinoline Derivatives as Potent and Selective α_2C-Adrenoceptor Antagonists

  摘要：

  Starting from two acridine compounds identified in a high-throughput screening campaign (1 and 2, Table 1), a series of 4-aminoquinolines was synthesized and tested for their properties on the human alpha(2)-adrenoceptor subtypes (alpha(2A), alpha(2B), and alpha(2C.)). A number of compounds with good antagonist potencies against the alpha(2C)-adrenoceptor and excellent subtype selectivities over the other two subtypes were discovered. For example, (R)-{4-[4-(3,4-dimethylpiperazin-1-yl) phenylamino] quinolin- 3- yl} methanol 6j had an antagonist potency of 8.5 nM against, and a subtype selectivity of more than 200-fold for, the alpha(2C)-adrenoceptor. Investigation of the structure-activity relationship identified a number of structural features, the most critical of which was an absolute need for a substituent in the 3-position of the quinoline ring. The 3-position on the piperazine ring was also found to play an appreciable role, as substitutions in that position exerted a significant and stereospecific beneficial effect on the alpha(2C)-adrenoceptor affinity and potency. Replacing the piperazine ring proved difficult, with 1,4-diazepanes representing the only viable alternative.

  DOI：

  10.1021/jm060262x
• 作为产物：
  描述：

  2-((4-nitrophenyl)amino)ethyl methanesulfonate 在 palladium on activated charcoal TEA 、 一水合肼 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 二氯甲烷 为溶剂， 反应 70.0h， 生成 N1-(2-(吡咯烷-1-基)乙基)苯-1,4-二胺
  参考文献：
  名称：

  Structure−Activity Relationship of Quinoline Derivatives as Potent and Selective α_2C-Adrenoceptor Antagonists

  摘要：

  Starting from two acridine compounds identified in a high-throughput screening campaign (1 and 2, Table 1), a series of 4-aminoquinolines was synthesized and tested for their properties on the human alpha(2)-adrenoceptor subtypes (alpha(2A), alpha(2B), and alpha(2C.)). A number of compounds with good antagonist potencies against the alpha(2C)-adrenoceptor and excellent subtype selectivities over the other two subtypes were discovered. For example, (R)-{4-[4-(3,4-dimethylpiperazin-1-yl) phenylamino] quinolin- 3- yl} methanol 6j had an antagonist potency of 8.5 nM against, and a subtype selectivity of more than 200-fold for, the alpha(2C)-adrenoceptor. Investigation of the structure-activity relationship identified a number of structural features, the most critical of which was an absolute need for a substituent in the 3-position of the quinoline ring. The 3-position on the piperazine ring was also found to play an appreciable role, as substitutions in that position exerted a significant and stereospecific beneficial effect on the alpha(2C)-adrenoceptor affinity and potency. Replacing the piperazine ring proved difficult, with 1,4-diazepanes representing the only viable alternative.

  DOI：

  10.1021/jm060262x

文献信息

• PYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF AND MEDICAL USE THEREOF
  申请人：Ancureall Pharmaceutical (Shanghai) Co., Ltd.

  公开号：US20210101881A1

  公开（公告）日：2021-04-08

  The present invention discloses a pyrimidine compound, a preparation method thereof and a medical use thereof. Specifically, the present invention discloses a pyrimidine compound represented by formula (I), pharmaceutically acceptable salts thereof, a preparation method thereof, and a use thereof as a cyclin-dependent kinase 9 (CDK9) inhibitor, particularly for the treatment of cancer. The definition of each group in formula (I) is the same as that in the specification.

  本发明公开了一种嘧啶化合物，其制备方法及医药用途。具体地，本发明公开了一种由式(I)表示的嘧啶化合物，其药学上可接受的盐，其制备方法，以及作为细胞周期依赖性激酶9（CDK9）抑制剂的用途，特别用于癌症治疗。式(I)中每个基团的定义与规范中的相同。
• [EN] THIAZOLE AND OXAZOLE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE À BASE DE THIAZOLE ET D'OXAZOLE
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009032667A1

  公开（公告）日：2009-03-12

  The present invention provides thiazole and oxazole compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

  本发明提供噻唑和氧唑化合物，含有这些化合物的组合物，以及用作药用剂的制备方法和使用方法。
• Kinase Inhibitors
  申请人：Wurster A. Julie

  公开号：US20070032478A1

  公开（公告）日：2007-02-08

  The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

  本发明涉及有机分子，能够调节酪氨酸激酶信号传导，以调节、调控和/或抑制异常细胞增殖。
• N-alkylamino secondary para-phenylenediamine, composition for dyeing keratin fibers comprising such a para-phenylenediamine, processes using this composition and uses thereof
  申请人：Sabelle Stephane

  公开号：US20060026772A1

  公开（公告）日：2006-02-09

  The present disclosure relates to novel N-alkylamino secondary para-phenylenediamines; a composition for dyeing keratin fibers, for example, human keratin fibers such as the hair, comprising, in a medium suitable for dyeing, at least one such N-alkylamino secondary para-phenylenediamine; a process for dyeing keratin fibers comprising applying this composition; and the uses of this composition in the form of a dyeing “kit”.

  本公开涉及新颖的N-烷基胺次级对苯二胺；一种用于染色角蛋白纤维的组合物，例如，人类角蛋白纤维如头发，包括在适合染色的介质中，至少含有这种N-烷基胺次级对苯二胺；一种染色角蛋白纤维的方法，包括应用这种组合物；以及这种组合物作为染色“套件”的用途。
• Kinase inhibitors
  申请人：Allergan, Inc.

  公开号：US07749530B2

  公开（公告）日：2010-07-06

  The present invention relates to drug delivery systems comprising ocular implant, which include organic molecules, capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation, in combination with a polymer, which polymer serves to control, modify, modulate and/or slow the release of the therapeutic component into the environment of the eye in which said composite is placed.

  本发明涉及药物输送系统，包括眼内植入物，其中包括有机分子，能够调节酪氨酸激酶信号转导，以调节、调节和/或抑制异常细胞增殖，与聚合物结合使用，该聚合物用于控制、修改、调节和/或减缓治疗成分释放到所放置的眼部环境中。